As we approach 2016, we would like to take this opportunity to thank our Editors, Reviewers, Authors and Industry Supporters for their valuable contri

   
CO-NEWSLETTER-LOGO withdate
SABCS2016-560x100
***

As we approach 2016, we would like to take this opportunity to thank our Editors, Reviewers, Authors and Industry Supporters for their valuable contribution and support of the journal.

2015 was an exciting year for the journal, as highlighted by:

An increased Impact Factor of 1.785 as published in the 2014 Journal Citation Reports, Science Edition (Thomson Reuters 2015)
458 article submissions (as of December 17, 2015) – a new record for the journal!
Increase in visitors to www.current-oncology.com - Recent stats from Google Analytics, Google’s web site traffic analysis application, have shown over a 7% increase in the number of visitors to the website over the past year
Publication of the supplement Updated Guidelines, Consensus and Evidence-Based Reports in Breast Cancer – articles from this supplement are amongst the top viewed this year by our readership

We have exciting plans for the journal in 2016 to ensure it continues to strengthen and grow, both within Canada and Internationally. Stay tuned for more information in future newsletters!

Best wishes for a happy holiday season,

logo70

Multimed Inc.
Publisher of Current Oncology
www.multi-med.com

***
CO Twitter Banner Ad
***
InPress-CON

Volume 22, Number 6 (December 2015)

The latest issue of Current Oncology is now available online. Please visit the following link to view full text articles from this issue:
http://www.current-oncology.com/index.php/oncology/issue/current/showToc

***
LookingAhead-CON

Upcoming in Current Oncology

The future table of contents for Current Oncology, Volume 23, Number 1 (February 2016) is now available. For the most up-to-date listing of scheduled papers, please visit the following link:
http://www.current-oncology.com/index.php/oncology/about/futureTOC

***
EditorSpotlight
Mvc-012s

Jeff Lipton, PhD MD FRCPC
Editor of our Medical Oncology (Hematology) Section (since December 2014)

Jeff Lipton is Professor of Medicine at the University of Toronto and Staff Physician on the Leukemia and Allogeneic Blood and Marrow Transplant Services at the Princess Margaret Hospital. He received an honors BSc in Biochemistry at the University of Calgary and went on to a PhD in Biochemistry at the University of Western Ontario. An MRC post-doctoral fellowship at the Weizmann Institute in Israel with Leo Sachs led to his developing interests in leukemia. After a short time as a junior staff at the University of Connecticut, he had a mid-life crisis and went back to Calgary to go to medical school, followed by a residency in Internal Medicine. He then completed sub-specialty training in Medical Oncology at the University of Toronto and stayed on at the PMH as a staff physician. His clinical practice is in chronic leukemias and bone marrow failure syndromes as well as allogeneic stem cell transplant. Research interests in particular are in CML and its therapy, outcomes and supportive care in BMT, and in the therapy of bone marrow failure syndromes. Jeff served on the Unrelated Donor Transplant Advisory Board of OneMatch, Past President of the Canadian Bone Marrow Transplant Group (CBMTG), was an advisor to the Center for Research on Bone Marrow Transplantation (CIBMTR), has served on the Clinical Trials Group of the CBMTG, was Director of the Allogeneic Stem Cell Transplant Program at PMH, is Head of the CML Study Group at PMH and is on several international advisory boards relating to the therapy of CML including the International CML Foundations and the European Leukemia Net (ELN). He has authored or co-authored more than 300 peer reviewed papers and 475 abstracts.

***
HaveYouHeard-CON

No Authors Fees for Clinical Research and Clinical Trial Articles: Until Dec 31, 2015

560x100 Banner

Current Oncology is seeking high-quality original clinical research and clinical trial articles. Areas may include research related to treatment, prevention, diagnostic, screening, and quality of life. Articles submitted should contain information that is relevant directly to clinical oncology practice, and have clear potential for application to the current or future practice of cancer medicine.

To help encourage submissions, Current Oncology will waive Standard Author Fees for all original clinical research and clinical trial articles, submitted between July 1st and December 31st, 2015.

View our full announcement for more details.

***

Current Oncology is Seeking Reviewers

Current Oncology is always seeking qualified and dedicated reviewers to assist with the manuscript review process. As a reviewer you will be asked to read and critique articles. Reviewers play an integral part in ensuring that the high standards of Current Oncology are met and that the articles published are of interest to the oncology community. Please take a moment to register on our website.

***

Register as a Reader to View Current Oncology

Starting with the February 2016 issue, there will be a 6 month embargo on articles published in Current Oncology. Articles under embargo can be accessed by registered readers. Registering as a reader is SIMPLE and FREE.

Already have an account with the journal as an Author or Editor? Please visit the Current Oncology website and login to your account. Once you have signed in, click on “Edit my profile” under the heading “My Account”. Ensure that the box beside “Reader” is selected under “Roles”.

If you do not have an account with the Current Oncology website, visit our Log in / Register page at www.current-oncology.com to register to today.

***
ReadersChoice-COn

Have you had the chance to view these Current Oncology “Most-Read” articles?

Most Read Articles in PubMed Central (November 2015)

Legalizing euthanasia or assisted suicide: the illusion of safeguards and controls
Pereira J.
Curr Oncol. 2011 Apr;18(2):e38-45

A legal right to die: responding to slippery slope and abuse arguments
Benatar D.
Curr Oncol. 2011 Oct;18(5):206-7

Management of arthralgias associated with aromatase inhibitor therapy
Thorne C.
Curr Oncol. 2007 Dec;14 Suppl 1:S11-9

Most Read Recently* Published Articles at www.current-oncology.com

Locoregional therapy of locally advanced breast cancer: a clinical practice guideline
Brackstone M, Fletcher GG, Dayes IS, Madarnas Y, SenGupta SK, Verma S; Members of the Breast Cancer Disease Site Group
Curr Oncol. 2015 Mar;22(Suppl 1):S54-66. doi: 10.3747/co.22.2316

Clinical challenges in patients with cancer-associated thrombosis: Canadian expert consensus recommendations
Carrier M, Lazo-Langner A, Shivakumar S, Tagalakis V, Gross PL, Blais N, Butts CA, Crowther M
Curr Oncol. 2015 Feb;22(1):49-59. doi: 10.3747/co.22.2392

Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelines
Joy AA, Ghosh M, Fernandes R, Clemons MJ
Curr Oncol. 2015 Mar;22(Suppl 1):S29-42. doi: 10.3747/co.22.2360

*Published within past 12 months

***
300 x 80px-01
MayaStern2

After 5 years with no evidence of disease, survivors of childhood cancer may be considered "cured" but in reality, they're not cured at all. Most survivors face a lifetime of long- and late-term effects of the treatment they received as a child. Adult cancer treatments that are given to children result in years of ill health, as you will discover in Maya’s posts below:

The Long-Term Effects of Childhood Cancer

Battle Scars

***
QuickLinks-CON
***

Contact Us

Email-CON
 
Address-CON
 
Phone-CON
 
Web-CON
twitter
1px